A Case of Radiation Recall Dermatitis after Hormonal Therapy of Letrozol (Femara(R)).
- Author:
Ji Young AHN
1
;
Ji Young KIM
;
Seong Jun SEO
;
Chang Kwun HONG
;
Kye Yong SONG
Author Information
1. Department of Dermatology, College of Medicine, Chung-Ang University, Seoul, Korea. drseo@hanafos.com
- Publication Type:Case Report
- Keywords:
Radiation recall dermatitis;
Letrozol (Femara(R))
- MeSH:
Aromatase;
Drug Therapy;
Interferons;
Radiodermatitis*;
Simvastatin;
Tamoxifen
- From:Korean Journal of Dermatology
2006;44(1):83-85
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Radiation recall dermatitis gap (RRD) is the development of an inflammatory reaction throughout a previously irradiated area, precipitated by the administration of certain drugs. Usually chemotherapeutic agents have been associated with RRD, but other drugs reported include tamoxifen, interferon alfa-2b, simvastatin, and antituberculous drugs. We present a case of RRD after chemotherapy with letrozol (Femara(R)). Letrozol is a third generation aromatase inhibitor, which acts as an anti-estrogen agent. This is the first reported case of RRD triggered by letrozol.
